FL Treatment Tool
Challenging the Current Treatment Paradigm for Patients With Follicular Lymphoma: Recent and Emerging Evidence

Released: March 31, 2023

Expiration: December 14, 2024

References

Axicabtagene ciloleucel [prescribing information]. Santa Monica, CA: Kite Pharma, Inc.; 2022.

Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: A report from the clinical advisory committee. Blood. 2022;140:1229-1253.

Copanlisib [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2022.

Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:298-308.

Jacobsen E. Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol. 2022; 97: 1638-1651.

Morschhauser, F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol.2020;21:1433-1442.

Mosunetuzumab-axgb [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2022.

Nastoupil LJ, Flowers CR, Leonard JP. Sequencing of therapies in relapsed follicular lymphoma. Hematology Am Soc Hematol Educ Program. 2018;2018:189-193.

National Comprehensive Cancer Network. Clinical practice guidelines in oncology: B-cell lymphomas. v.1.2023. nccn.org. Accessed February 21, 2023.

Tazemetostat [prescribing information]. Cambridge, MA: Epizyme, Inc.; 2020.

Tisagenlecleucel [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation.; 2022.

Access to and use of this Interactive Decision Support Tool titled, “Interactive Decision Support Tool: Expert Treatment Guidance for Follicular Lymphoma” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices for monitoring or treating individuals with follicular lymphoma. The information provided is based on the NCCN, and ESMO guideline recommendations and expert guidance of John M. Burke, MD; Christopher R. Flowers, MD, MS; Jean Koff, MD, MSc; Jeffrey Sharman, MD; and Pallawi Torka, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Decision Support Tool: Expert Treatment Guidance for Follicular Lymphoma” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2023 Clinical Care Options, LLC. All rights reserved.

Program Content